Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Manuela Mancini
Observed names:
M Mancini,
M. Mancini,
MANCINI, MANUELA,
Mancini, Manuela
Institutions:
Istituto di Ematologia di Bologna,
University of Bologna
Observed institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Istituto di Ematologia di Bologna,
Istituti di Ricovero e Cura a Carattere Scientifico,
University of Bologna
ORCID:
0000-0002-2972-5609
Observed ORCID:
0000-0002-2972-5609
OpenAlex ID:
A5045537458
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
2018
·
Simona Soverini
, Manuela Mancini
, et al.
·
Molecular Cancer
·
230
PDF
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition
2014
·
M R Sapienza
, F Fuligni
, et al.
·
Leukemia
·
192
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
2015
·
Simona Soverini
, Caterina de Benedittis
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
81
Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein–protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis
2010
·
Valentina Corradi
, Manuela Mancini
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
81
Best Practices in Chronic Myeloid Leukemia Monitoring and Management
2016
·
Simona Soverini
, Caterina De Benedittis
, et al.
·
The Oncologist
·
65
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
2016
·
Simona Soverini
, Caterina De Benedittis
, et al.
·
Oncotarget
·
61
PDF
A New Nonpeptidic Inhibitor of 14-3-3 Induces Apoptotic Cell Death in Chronic Myeloid Leukemia Sensitive or Resistant to Imatinib
2010
·
Manuela Mancini
, Valentina Corradi
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
60
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents
2007
·
Marco Radi
, Emmanuele Crespan
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
56
The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities
2021
·
Samantha Bruno
, Manuela Mancini
, et al.
·
International Journal of Molecular Sciences
·
45
PDF
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
2017
·
G Martinelli
, M Mancini
, et al.
·
Leukemia
·
42
PDF
Computational techniques are valuable tools for the discovery of protein–protein interaction inhibitors: The 14-3-3σ case
2011
·
Valentina Corradi
, Manuela Mancini
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
42
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway
2014
·
P P Piccaluga
, M Rossi
, et al.
·
Leukemia
·
40
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
2021
·
Simona Soverini
, Sara De Santis
, et al.
·
International Journal of Molecular Sciences
·
38
PDF
14‐3‐3 Ligand Prevents Nuclear Import of c‐ABL Protein in Chronic Myeloid Leukemia
2009
·
Manuela Mancini
, Nevena Veljkovic
, et al.
·
Traffic
·
36
PDF
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells
2010
·
Manuela Mancini
, Sara Petta
, et al.
·
Cellular Signalling
·
35
C6‐Unsubstituted Pyrazolo[3,4‐d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines
2008
·
Maria Alessandra Santucci
, Valentina Corradi
, et al.
·
ChemMedChem
·
32
PDF
Multiple phosphorylation sites at the C-terminus regulate nuclear import of HCMV DNA polymerase processivity factor ppUL44
2011
·
Gualtiero Alvisi
, Oriano Marin
, et al.
·
Virology
·
31
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia
2022
·
Simona Soverini
, Sara De Santis
, et al.
·
Leukemia
·
30
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
2009
·
Manuela Mancini
, Valentina Corradi
, et al.
·
Leukemia Research
·
29
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
2016
·
Simona Soverini
, Caterina De Benedittis
, et al.
·
BMC Cancer
·
28
PDF
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
2022
·
Sara De Santis
, Cecilia Monaldi
, et al.
·
OncoTargets and Therapy
·
26
PDF
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
2020
·
Margherita Martelli
, Cecilia Monaldi
, et al.
·
International Journal of Molecular Sciences
·
26
PDF
Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples
2010
·
Claudio Agostinelli
, Elena Sabattini
, et al.
·
Applied immunohistochemistry & molecular morphology
·
26
RAD 001 (everolimus) prevents mTOR and Akt late re‐activation in response to imatinib in chronic myeloid leukemia
2009
·
Manuela Mancini
, Sara Petta
, et al.
·
Journal of Cellular Biochemistry
·
26
RETRACTED: Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606
2006
·
Manuela Mancini
, Gianluca Brusa
, et al.
·
Leukemia Research
·
26
Show more works
View as search
Works count:
135
Citation count:
1,824
H-index:
26
I10-index:
44
Year
Topic
Type